Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)
Academic Article
Overview
MeSH Major
Adenocarcinoma
Antineoplastic Combined Chemotherapy Protocols
Neoplasm Recurrence, Local
Pancreatic Neoplasms
abstract
Vatalanib was well tolerated as a second-line therapy and resulted in favorable 6-month survival rate in patients with metastatic pancreatic cancer, compared with historic controls.